What is the current revenue generated by the product and what is the projected revenue for the next quarter? 
on and do I think we'll do it in a reasonable time? $5 billion [Indecipherable] yes, I do. And I think it's done. The growth rate here is reflective of not only the size of the market, but the need and utility and affordability of the product. And I think it's just as I've said many times, it's a very different market where affordability and the utility, the access, all those things make this a mass market product, not a niche.
And it's designed for that, it's priced for that, it's a very profitable product. And we're going through the large-scale scale up of addressing that kind of growth, which is unprecedented for products in our space. So do I think it can grow to that sort of level? I won't -- I won't jinx anything by trying to make some prognostication about $10 billion, but I would say that I think it's got enormous potential and it's got potential beyond glucose. It's got potential as a wearable in other analytes and other products over time.
We have R&D programs under way, not only for the repeated enhancement improvement, expansion of Libre, but also into other categories beyond diabetes and other analyzers and so forth. So I think that there's just a lot of things that will evolve over the coming years here that today people aren't even contemplating with the product. We're going as hard as we can at the glucose opportunity, which is enormous, but there is so much more beyond that, that I think at least your aspirational consideration to be honest has validity [Phonetic] I just -- I'm not ready to put any numbers around it.
Matthew Taylor -- UBS -- Analyst
Thanks. And then maybe one last follow-up. That was a great answer, but just wanted to get your feedback on what you think is misunderstood about Libre today when you get feedback from investors that bubbles up to you, where do you think that the internal view of Libre really differs from the Street's perception or people's perception?
Miles D. White -- Chairman of the Board and Chief Executive Officer
[Indecipherable] only ask the COO. He's been living with it a long time.
Robert B. Ford -- President and Chief Operating Officer
Yeah, I think when we went out about this several years ago, the challenge here, Matt, wasn't to get an accurate reading of glucose from the interstitial fluid. Navigator when we had launched it back in 2008, we were able to do that. It was very accurate and we were able to get an accurate reading. The challenge that we went about with Libre is how to do that in a way that is cost-effective for the health systems and for consumers and for -- and for all of that.
So that was what we really went after is, how can you get that accurate reading at a cost position at the core of Libre and you might remember at the time Navigator at the time was considered the most accurate sensor. In the core of Libre is that chemistry, is that core technology of Navigator, which provides accurate reliable readings. But we're able to do that a cost position that now makes sense for the insurance and for the payer community, and the health systems to cover it. It wasn't a question of whether the outcomes were right or whether the outcomes were enough. They were convinced that the outcomes were there for sensor based glucose monitoring. It was just -- can I now do it in a way that makes sense for me to do it on a mass scale and Miles has talked about this about mass scale, that's what we went after 10 years ago. And that's at the core and I think maybe that's misunderstood because a lot of this discussion gets focused on well accuracy at this level and accuracy at that level.
And the reality is accuracy is obviously important, but our goal here is to make this massively available without having to sacrifice accuracy and the fact that we price it at a different price point, wouldn't say necessarily imply that it's somehow missing something. We just had a different strategy, and different view of what we could do.
Miles D. White -- Chairman of the Board and Chief Executive Officer
The only product out there that the Street has been able to compare it to is ex
on and do I think we'll do it in a reasonable time? $5 billion [Indecipherable] yes, I do. And I think it's done. The growth rate here is reflective of not only the size of the market, but the need and utility and affordability of the product. And I think it's just as I've said many times, it's a very different market where affordability and the utility, the access, all those things make this a mass market product, not a niche.
And it's designed for that, it's priced for that, it's a very profitable product. And we're going through the large-scale scale up of addressing that kind of growth, which is unprecedented for products in our space. So do I think it can grow to that sort of level? I won't -- I won't jinx anything by trying to make some prognostication about $10 billion, but I would say that I think it's got enormous potential and it's got potential beyond glucose. It's got potential as a wearable in other analytes and other products over time.
We have R&D programs under way, not only for the repeated enhancement improvement, expansion of Libre, but also into other categories beyond diabetes and other analyzers and so forth. So I think that there's just a lot of things that will evolve over the coming years here that today people aren't even contemplating with the product. We're going as hard as we can at the glucose opportunity, which is enormous, but there is so much more beyond that, that I think at least your aspirational consideration to be honest has validity [Phonetic] I just -- I'm not ready to put any numbers around it.
Matthew Taylor -- UBS -- Analyst
Thanks. And then maybe one last follow-up. That was a great answer, but just wanted to get your feedback on what you think is misunderstood about Libre today when you get feedback from investors that bubbles up to you, where do you think that the internal view of Libre really differs from the Street's perception or people's perception?
Miles D. White -- Chairman of the Board and Chief Executive Officer
[Indecipherable] only ask the COO. He's been living with it a long time.
Robert B. Ford -- President and Chief Operating Officer
 Yeah, I think when we went out about this several years ago, the challenge here, Matt, wasn't to get an accurate reading of glucose from the interstitial fluid. Navigator when we had launched it back in 2008, we were able to do that. It was very accurate and we were able to get an accurate reading. The challenge that we went about with Libre is how to do that in a way that is cost-effective for the health systems and for consumers and for -- and for all of that.
So that was what we really went after is, how can you get that accurate reading at a cost position at the core of Libre and you might remember at the time Navigator at the time was considered the most accurate sensor. In the core of Libre is that chemistry, is that core technology of Navigator, which provides accurate reliable readings. But we're able to do that a cost position that now makes sense for the insurance and for the payer community, and the health systems to cover it. It wasn't a question of whether the outcomes were right or whether the outcomes were enough. They were convinced that the outcomes were there for sensor based glucose monitoring. It was just -- can I now do it in a way that makes sense for me to do it on a mass scale and Miles has talked about this about mass scale, that's what we went after 10 years ago. And that's at the core and I think maybe that's misunderstood because a lot of this discussion gets focused on well accuracy at this level and accuracy at that level.
And the reality is accuracy is obviously important, but our goal here is to make this massively available without having to sacrifice accuracy and the fact that we price it at a different price point, wouldn't say necessarily imply that it's somehow missing something. We just had a different strategy, and different view of what we could do.
Miles D. White -- Chairman of the Board and Chief Executive Officer
The only product out there that the Street has been able to compare it to is ex